An Open-Label Extension of Two Phase 3 Studies Evaluating Long-Term Efficacy of FMX101 4% Minocycline Foam for the Treatment of Acne Vulgaris

Linda Stein Gold; Sunhil Dhawan; Jonathan Weiss; Zoe Diana Draelos; Herman Ellman; Iain Stuart

doi:10.25251/skin.3.supp.1

Linda Stein Gold

Henry Ford Health System

Sunhil Dhawan

Center for Dermatology Clinical Research, Inc

Jonathan Weiss

Gwinnett Dermatology

Zoe Diana Draelos

Dermatology Consulting Services

Herman Ellman

Foamix Pharmaceuticals, Inc.

Iain Stuart

Foamix Pharmaceuticals, Inc.

Keywords

acne, minocycline

Abstract

Abstract not available.

References

1. Biswal I, Gaind R, Kumar N, et al. In vitro antimicrobial susceptibility patterns of Propionibacterium acnes isolated from patients with acne vulgaris. J Infect Dev Ctries. 2016;10(10):1140-1145.

2. Gold LS, Dhawan S, Weiss J, et al. A novel topical minocycline foam for the treatment of moderateto-severe acne vulgaris: results of 2 randomized, double-blind, phase 3 studies. J Am Acad Dermatol. 2019;80(1):168-177.

3. Raoof J, Hooper D, Moore A, et al. Efficacy and safety of a novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: a phase 3 study. J Am Acad Dermatol. 2019; Jun 1 [Epub ahead of print].

Poster PDF

Published

Nov 9, 2019

DOI https://doi.org/10.25251/skin.3.supp.1

How to Cite

[1]

Gold, L.S., Dhawan, S., Weiss, J., Draelos, Z.D., Ellman, H. and Stuart, I. 2019. An Open-Label Extension of Two Phase 3 Studies Evaluating Long-Term Efficacy of FMX101 4% Minocycline Foam for the Treatment of Acne Vulgaris. SKIN The Journal of Cutaneous Medicine. 3, (Nov. 2019), S1. DOI:https://doi.org/10.25251/skin.3.supp.1.

Issue

Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas

Section

Acne & Rosacea

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Mark Lebwohl, Michael Bukhalo, Linda Stein Gold, Michelle Pelle, Bradley Glick, Mar Llamas-Velasco, Samuel Sanchez-Rivera, Tianyu Zhan, Leonidas Drogaris, Kevin Douglas, Greg St. John, Ramon Espaillat, Robert Bissonnette, A Phase 3b Study Evaluating Safety and Efficacy of Risankizumab in Adult Patients with Moderate-to-Severe Plaque Psoriasis with Palmoplantar (Non-Pustular) Involvement , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 6 (2023): November 2023 Issue
James Del Rosso, Leon Kircik, Linda Stein Gold, Hilary Baldwin, Jonathan Weiss, David Pariser, Valerie Callender, Edward Lain, Michael Gold, Kenneth Beer, Zoe Draelos, Neil Sadick, ; Radhakrishnan Pillai, Varsha Bhatt, Emil Tanghetti, Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: Phase 2 Study of the First Triple-Combination Drug , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Linda Stein Gold, Jonathan S Weiss, Lawrence Green, Leon Kircik, Lauren Miller, Abby Jacobson, Susan Harris, Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% (HP/TAZ) Lotion in Patients with Baseline Body Surface Area of 6 -12% , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
Robert Bissonnette, Linda Stein Gold, Leon Kircik, Stephen Tyring, Anna Tailman, April Armstrong, Efficacy of Tapinarof Cream by Body Region in Subjects With Plaque Psoriasis in a Phase 2b Randomized Controlled Study , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
James Q Del Rosso, Linda Stein Gold, Leon Kircik, Neal Bhatia, Neil Sadick, Matthew Zirwas, Edward Lain, Iain Stuart, Integrated Safety and Efficacy Analysis of FMX103 1.5% Topical Minocycline Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea: Results From Two Phase 3 Studies , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
James Q Del Rosso, Linda Stein Gold, Leon Kircik, Neal D Bhatia, Neil Sadick, Matthew Zirwas, Edward Lain, Iain Stuart, Integrated Safety and Efficacy Analysis of FMX103 1.5% Topical Minocycline Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea: Results From Two Phase 3 Studies , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
Linda Stein Gold, James Del Rosso, Leon Kircik, Neal D Bhatia, Deirdre Hooper, Walter Nahm, Iain Stuart, Open-Label Extension Study Evaluating the Long-Term Safety, Efficacy, and Tolerability of FMX103 1.5% Topical Minocycline Foam in the Treatment of Moderate-to-Severe Facial Papulopustular Rosacea , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
James Del Rosso, Linda Stein Gold, Leon Kircik, Andrew Alexis, Seemal R. Desai, Vassilis Stakias, Iain Stuart, Integrated Efficacy of FMX101 4% Topical Minocycline Foam for the Treatment of Moderate-to-Severe Acne Vulgaris: Analyses of Efficacy in Clinically Relevant Subgroups of Patients , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Jerry Tan, James Del Rosso, Jonathan Weiss, Linda Stein Gold, Fran Cook-Bolden, Lawrence Eichenfeld, Emil Tanghetti, Alessandra Ali? Saenz, Faiz Ahmad, Trifarotene 50 µg/G Cream for Treatment of Acne Vulgaris – A Summary of Two Randomized Trials and a Long-Term Safety Study , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
Linda Stein Gold, Hilary Baldwin, Fran Cook-Bolden, Lawrence Green, Glynis Ablon, Neil Sadick, Jonathan Weiss, Eric Guenin, Efficacy and Safety of Tazarotene 0.045% Lotion in Female Patients with Moderate-to-Severe Acne: Post Hoc Analysis by Age , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)

1 2 3 4 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Similar Articles

Most read articles by the same author(s)